{
  "source": "PA-Med-Nec-Cetrotide.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2173-7\nProgram Prior Authorization/Medical Necessity\nMedication Cetrotide® (cetrorelix acetate)*\nP&T Approval Date 8/2019, 8/2020, 8/2021, 8/2022, 8/2023, 5/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nCetrotide (cetrorelix acetate) and ganirelix acetate are synthetic decapeptides with\ngonadotropin-releasing hormone (GnRH) antagonist activity. These agents are indicated to\ninhibit premature leuteinizing hormone (LH) surges in women undergoing ovarian stimulation\nfollowed by insemination or assisted reproductive technology (ART) procedures.\n2. Coverage Criteriaa:\nA. Ovarian Stimulation\n1. Cetrotide (cetrorelix acetate)* will be approved based on one of the following criteria:\na. All of the following:\n(1) Diagnosis of infertility\n-AND-\n(2) One of the following exists:\n(a) Unexplained infertility\n(b) Endometriosis\n(c) Male factor infertility\n(d) Tubal factor infertility\n(e) Diminished ovarian reserve\n(f) Uterine factor infertility\n(g) Ovulatory dysfunction\n(h) Recurrent pregnancy loss\n(i) Failure to achieve conception with other treatment modalities\n-AND-\n(3) For the development of one or more follicles (ovarian stimulation)\n-AND-\n(4) Will be used in conjunction only with assisted reproductive technology (ART)\n-AND-\n© 2025 United HealthCare Services, Inc.\n1\n(5) History of failure, contraindication, or intolerance to ganirelix acetate (Merck and\nCo., Inc. and Organon Global Inc. formulations)\n-OR-\nb. All of the following:\n(1) Used for fertility preservation\n-AND-\n(2) The individual will undergo gonadotoxic therapy (e.g., exposure to cytotoxic\nagents, invasive surgery, prolonged hormonal ovarian suppression, radiation\ntherapy)\n-AND-\n(3) Will be used as part of an assisted reproductive technology (e.g., in vitro\nfertilization) procedure\n-AND-\n(4) History of failure, contraindication, or intolerance to ganirelix acetate (Merck and\nCo., Inc. and Organon Global Inc. formulations)\nAuthorization ",
    "y (e.g., in vitro\nfertilization) procedure\n-AND-\n(4) History of failure, contraindication, or intolerance to ganirelix acetate (Merck and\nCo., Inc. and Organon Global Inc. formulations)\nAuthorization will be issued for 2 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n*Infertility is typically excluded from coverage. Please refer to plan specifics to determine exclusion\nstatus.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply Limits and/or Step Therapy may also be in place\n4. References:\n1. Cetrotide [package insert]. Rockland, MA: EMD Serono, Inc.; June 2024.\n2. Ganirelix acetate [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.;\nNovember 2024.\n3. Sahakyan M, Harlow BL, Hornstein MD. Influence of age, diagnosis, and cycle number on\npregnancy rates with gonadotropin-induced controlled ovarian hyperstimulation and\nintrauterine insemination. Fertil Steril 1999; 72: 500-504.\n4. Ganirelix acetate [package insert]. Jersey City, NJ: Organon Global Inc.; February 2024.\n© 2025 United HealthCare Services, Inc.\n2\nProgram Prior Authorization/Medical Necessity - Cetrotide (cetrorelix acetate)\nChange Control\n8/2019 New program.\n8/2020 Annual review with no changes to coverage criteria. Updated\nformatting.\n8/2021 Annual review with no changes to the clinical coverage criteria.\nUpdated background, formatting and references.\n8/2022 Annual review. Added Organon Global ganirelix acetate generic as a\npreferred product. Updated exclusion statements and references.\n8/2023 Annual review. Updated background and references.\n5/2024 Added cove",
    "l review. Added Organon Global ganirelix acetate generic as a\npreferred product. Updated exclusion statements and references.\n8/2023 Annual review. Updated background and references.\n5/2024 Added coverage criteria for fertility preservation for iatrogenic\ninfertility. Updated term \"controlled ovarian stimulation” to “ovarian\nstimulation”.\n6/2025 Updated coverage criteria for fertility preservation for iatrogenic\ninfertility to include additional examples of gonadotoxic therapy such\nas prolonged hormonal ovarian suppression. Updated references.\n© 2025 United HealthCare Services, Inc.\n3"
  ]
}